Fortress Biotech, Inc. (FBIO) is a Biotechnology company in the Healthcare sector, currently trading at $2.42. It has a SharesGrow Score of 45/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Valuation: FBIO trades at a trailing Price-to-Earnings (P/E) of 9.5 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.07.
Financials: revenue is $61M, -4.7%/yr average growth. Net income is $33M (loss), growing at +27.5%/yr. Net profit margin is -53.7% (negative). Gross margin is 0% (-59.4 pp trend).
Balance sheet: total debt is $67M against $50M equity (Debt-to-Equity (D/E) ratio 1.35, moderate). Current ratio is 2.49 (strong liquidity). Debt-to-assets is 36.2%. Total assets: $186M.
Analyst outlook: 6 / 6 analysts rate FBIO as buy (100%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 50/100 (Partial), Moat 0/100 (Fail), Future 100/100 (Pass), Income 10/100 (Fail).
